SearcharxivSearch

arXiv subjects

James Brian Byrd

Publications and source records attributed to James Brian Byrd.

3 recordsLinked to original sources

Sodium Allostasis: A New Paradigm for Understanding Cardiovascular Volume Accommodation

Arthur Guyton's classic pressure-natriuresis model posits that dietary sodium challenges induce a transient expansion of blood volume that the kidneys rapidly rectify to restore a strict homeostatic baseline, reducing cardiac output to baseline values despite continued higher sodium diet. While this model remains a cornerstone of medical education, it was established in animal models that included surgical reductions in renal mass. Decades of direct human evidence, including long-term balance and spaceflight simulation studies, show that healthy individuals exhibit substantial, persistent plasma volume expansion and sustained cardiac output elevation during prolonged high-sodium intake with little effect on the mean arterial blood pressure. To reconcile these empirical inconsistencies, we propose "sodium allostasis" as an alternative regulatory framework. We argue that sodium regulation operates via two distinct mechanisms: a strict concentration homeostasis that maintains plasma sodium levels (~140 mEq/L) via dilution, and an allostatic accommodation that can sustain a persistently expanded blood volume and higher total body sodium mass. This paradigm fundamentally reframes salt sensitivity. Rather than a primary defect in renal sodium excretion, salt sensitivity reflects a failure of the vasculature to accommodate expanded plasma volume. Furthermore, human and animal data reveal that this chronic allostatic state carries a hidden, profound metabolic cost, forcing energy-intensive sodium reabsorption into poorly oxygenated renal medullary segments and inducing tissue hypoxia independent of blood pressure. Shifting focus from rigid homeostatic volume regulation to vascular accommodation and sodium allostasis provides an accurate physiological foundation for cardiovascular medicine and opens novel, vascular-targeted therapeutic pathways for hypertension and volume disorders.

q-bio.TO

Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure

The novel coronavirus SARS-CoV-2, which emerged in late 2019, has since spread around the world and infected hundreds of millions of people with coronavirus disease 2019 (COVID-19). While this viral species was unknown prior to January 2020, its similarity to other coronaviruses that infect humans has allowed for rapid insight into the mechanisms that it uses to infect human hosts, as well as the ways in which the human immune system can respond. Here, we contextualize SARS-CoV-2 among other coronaviruses and identify what is known and what can be inferred about its behavior once inside a human host. Because the genomic content of coronaviruses, which specifies the virus's structure, is highly conserved, early genomic analysis provided a significant head start in predicting viral pathogenesis and in understanding potential differences among variants. The pathogenesis of the virus offers insights into symptomatology, transmission, and individual susceptibility. Additionally, prior research into interactions between the human immune system and coronaviruses has identified how these viruses can evade the immune system's protective mechanisms. We also explore systems-level research into the regulatory and proteomic effects of SARS-CoV-2 infection and the immune response. Understanding the structure and behavior of the virus serves to contextualize the many facets of the COVID-19 pandemic and can influence efforts to control the virus and treat the disease.

q-bio.QM

Identification and Development of Therapeutics for COVID-19

After emerging in China in late 2019, the novel Severe acute respiratory syndrome-like coronavirus 2 (SARS-CoV-2) spread worldwide and as of early 2021, continues to significantly impact most countries. Only a small number of coronaviruses are known to infect humans, and only two are associated with the severe outcomes associated with SARS-CoV-2: Severe acute respiratory syndrome-related coronavirus, a closely related species of SARS-CoV-2 that emerged in 2002, and Middle East respiratory syndrome-related coronavirus, which emerged in 2012. Both of these previous epidemics were controlled fairly rapidly through public health measures, and no vaccines or robust therapeutic interventions were identified. However, previous insights into the immune response to coronaviruses gained during the outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) have proved beneficial to identifying approaches to the treatment and prophylaxis of novel coronavirus disease 2019 (COVID-19). A number of potential therapeutics against SARS-CoV-2 and the resultant COVID-19 illness were rapidly identified, leading to a large number of clinical trials investigating a variety of possible therapeutic approaches being initiated early on in the pandemic. As a result, a small number of therapeutics have already been authorized by regulatory agencies such as the Food and Drug Administration (FDA) in the United States, and many other therapeutics remain under investigation. Here, we describe a range of approaches for the treatment of COVID-19, along with their proposed mechanisms of action and the current status of clinical investigation into each candidate. The status of these investigations will continue to evolve, and this review will be updated as progress is made.

q-bio.QM